Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib + atezolizumab vs second novel hormonal therapy in metastatic castration-resistant prostate cancer
2020-000348-77Phase 3Completed
- Sponsor
- Exelixis, Inc.
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cabozantinib and atezolizumab in prostate cancer (PCa) (2 arms), sponsored by Exelixis, Inc. Primary endpoint: Progression-free survival. Started Jun 2020; status: completed.
02
Drugs
cabozantinibatezolizumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2020-000348-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000348-77.